Cybin to participate in the cantor global healthcare conference

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that doug drysdale, chief executive officer of cybin, and george tziras, chief executive officer of small pharma inc., will participate in a panel discussion titled “emerging therapeutic candidates for mental health” at.
CYBN Ratings Summary
CYBN Quant Ranking